Cardiovascular Drugs and Therapy

, Volume 13, Issue 5, pp 435–439 | Cite as

Beta-blockers for the Treatment of Hypertension in Patients with Diabetes: Exploring the Contraindication Myth

  • Sumit R. Majumdar


Purpose: To review the evidence supporting the “contraindications” (hypoglycemic unawareness, insulin resistance, and dyslipidemia) usually given as the reasons by physicians for not using beta blockers for treating hypertension in patients with diabetes mellitus. Methods: A research synthesis based on MEDLINE (January 1966 through January 1999), hand searches of pertinent references and textbooks, and consultation with experts. Results: There is little evidence to support the assertion that beta blockers should be routinely contraindicated in diabetes. Beta blockers have few clinically important effects on hypoglycemic awareness and recovery, insulin resistance and hyperglycemia, or lipid profiles. Moreover, when diabetics have been treated with beta blockers for hypertension or for the secondary prevention of myocardial infarction, they benefit as much, if not more, than nondiabetic patients. There may be many circumstances (e.g., hypertensive patients with coronary disease) under which beta blockers are the drugs of first choice for diabetic patients. Recommendations to use agents other than beta blockers (or low dose thiazide diuretics) for the treatment of hypertension in diabetes are based on these agents' effectiveness against surrogate endpoints, and not their proven benefit in preventing important clinical endpoints. Conclusions: Except for patients with brittle glycemic control, manifest hypoglycemic unawareness, renal parenchymal disease, or documented intolerance, beta blockers should no longer be considered routinely contraindicated in the presence of diabetes.

hypertension diabetes mellitus treatment beta blockers guidelines 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992;19:403–418.Google Scholar
  2. 2.
    Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: The Framingham Study. Circulation 1979;59:8–13.Google Scholar
  3. 3.
    Statement on hypertension in diabetes mellitus: Final report. Arch Int Med 1987;147:830–842.Google Scholar
  4. 4.
    Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: A systematic review and meta-analysis. JAMA 1997;277:739–745.Google Scholar
  5. 5.
    Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886–1892.Google Scholar
  6. 6.
    Klein R, Moss SE, Klein BE and Demets DL. Relation of ocular and systemic factors to survival in diabetes. Arch Int Med 1989;149:266–272.Google Scholar
  7. 7.
    Warram JH, Laffel LMB, Valsania P, Chrislieb AR, Krolewski AS. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Int Med 1991;151:1350–1356.Google Scholar
  8. 8.
    Myers MG, Carruthers SG, Leenen FHH, et al. Recommendations from the Canadian Hypertension Society Consensus Conference on the pharmacologic treatment of hypertension. Can Med Assoc J 1989;140:1141–1146.Google Scholar
  9. 9.
    Physicians Desk Reference, 50th Ed. Medical Economics Data Production Company, 1996.Google Scholar
  10. 10.
    Kaplan NM. Clinical Hypertension, 6th Ed. Williams and Wilkins, 1994: chapter 7.Google Scholar
  11. 11.
    Leese GP, Savage MW, Chattington PD, Vora JP. The diabetic patient with hypertension. Postgrad Med J 1996;72:263–268.Google Scholar
  12. 12.
    National High Blood Pressure Expert Panel Working Group. Hypertension in diabetes. Hypertension 1994;23:147–162.Google Scholar
  13. 13.
    Kaplan NM, Rosenstock J, Raskin P. A differing view of treatment of hypertension in patients with diabetes mellitus. Arch Int Med 1987;147:1160–1162.Google Scholar
  14. 14.
    Sowers JR, Zemel MB. Clinical implications of hypertension in the diabetic patient. Am J Hyper 1990;3:415–424.Google Scholar
  15. 15.
    Molnar GW, Read RC, Wright FE. Propranolol enhancement of hypoglycemic sweating. Clin Pharmacol Ther 1974;15:490–496.Google Scholar
  16. 16.
    Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin dependent diabetes mellitus and hypertension: A randomized controlled trial. Ann Intern Med 1997;126:955–959.Google Scholar
  17. 17.
    Lager I, Blohme G, Smith U. Effects of cardioselective and non-selective beta blockade on the hypoglycemic response in insulin dependent diabetes. Lancet 1979;1:458–462.Google Scholar
  18. 18.
    Herings RM, de Boer A, Striker BH, Leufkens HG, Porsius A. Hypoglycemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995;345:1195–1198.Google Scholar
  19. 19.
    Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997;278:40–43.Google Scholar
  20. 20.
    UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713–720.Google Scholar
  21. 21.
    Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy—an update. Hypertension 1995;26:869–879.Google Scholar
  22. 22.
    Manolio TA, Cutler JA, Furberg CD, et al. Trends in pharmacologic management of hypertension in the United States. Arch Int Med 1995;155:829–837.Google Scholar
  23. 23.
    Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of beta blocker therapy in patients with non-insulin dependent diabetes mellitus and coronary artery disease. Am J Cardiol 1996;77:1273–1277.Google Scholar
  24. 24.
    Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995;122:133–141.Google Scholar
  25. 25.
    Lasser NL, Grandits G, Caggiula AW, et al. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. Am J Med 1984;76(2A):52–66.Google Scholar
  26. 26.
    Samuelsson O, Hedner T, Persson B, et al. The role of diabetes mellitus and hypertriglyceridemia as coronary risk factors in treated hypertension: 15 years of follow-up of antihypertensive treatment in middle aged men in the Primary Prevention Trial in Goteborg, Sweden. J Int Med 1994;235:217–227.Google Scholar
  27. 27.
    The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413–2444.Google Scholar
  28. 28.
    Yusuf S, Peto R, Lewis JA, Collins R, Sleight P. Beta blockade during and after myocardial infarction: a review of the randomized controlled trials. Prog Cardiovasc Dis 1987;27:335–343.Google Scholar
  29. 29.
    Byington RP, Worthy J, Craven T, Furberg CD. Propranolol-induced changes and their prognostic significance after myocardial infarction: The Beta-Blocker Heart Attack Trial experience. Am J Cardiol 1990;65:1287–1291.Google Scholar
  30. 30.
    Gundersen T, Kuekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983;6:285–290.Google Scholar
  31. 31.
    Fleming TR, Demets DL. Surrogate endpoints in clinical trials: Are we being misled? Ann Intern Med 1996;125:605–613.Google Scholar
  32. 32.
    Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781–788.Google Scholar
  33. 33.
    Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nislodipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998;338:645–652.Google Scholar
  34. 34.
    Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620–625.Google Scholar
  35. 35.
    Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326–1331.Google Scholar
  36. 36.
    Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicentre Isradipine Diuretic Atherosclerosis Study (MIDAS): A randomized controlled trial. JAMA 1996;276:785–791.Google Scholar
  37. 37.
    Tatti P, Pahor M, Byington RP, DiMauro P, Guarisco R, Strollo F. Results of the Fosinopril Amlodipine Cardiovascular Events Trial (FACET) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM). Circulation 1997;96(Suppl I):I764.Google Scholar
  38. 38.
    De Bono G, Kaye CM, Roland E, Summers AJH. Acebutolol: Ten years of experience. Am Heart J 1985;109:1211–1223.Google Scholar
  39. 39.
    Boissel JP, Leizorovicz A, Piclolet H, et al. Secondary prevention after high-risk acute myocardial infarction with low dose acebutolol. Am J Cardiol 1990;66:251–260.Google Scholar
  40. 40.
    Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456–1462.Google Scholar
  41. 41.
    Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939–945.Google Scholar
  42. 42.
    Sawicki PT. Do ACE inhibitors offer specific benefits in the antihypertensive treatment of diabetic patients? 17 years of unfulfilled promises. Diabetologia 1998;41:598–602.Google Scholar
  43. 43.
    Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: A meta-analysis of randomized controlled trials. Arch Intern Med 1991;151:1769–1776.Google Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Sumit R. Majumdar
    • 1
  1. 1.Department of Ambulatory Care and PreventionHarvard Medical School and Harvard Pilgrim Health CareBoston

Personalised recommendations